Anti-Alzheimer's and Anti-inflammatory Activities of Compounds Isolated from *Solanum Mauritianum*

Authors

Luis Apaza Ticona^{1,2}, Borja Durán García¹, Marcos Humanes Bastante¹, Andreea Madalina Serban³, Ángel Rumero Sánchez¹

Affiliations

- 1 Department of Organic Chemistry, Faculty of Sciences, University Autónoma of Madrid, Cantoblanco, Madrid, Spain
- 2 Department of Pharmacology, Pharmacognosy and Botany, Faculty of Pharmacy, University Complutense of Madrid, Ciudad Universitaria s/n, Madrid, Spain
- 3 Maria Skłodowska Curie University Hospital for Children, Bucharest, Romania

Key words

Solanaceae, *Solanum mauritianum*, anti-inflammatory, anti-cholinesterase, anti-Alzheimer's

received 04.08.2021

revised 21.09.2021

accepted 09.11.2021

Bibliography

Planta Med Int Open 2022; 9: e1–e11

DOI 10.1055/a-1696-6741

ISSN 2509-9264

© 2022. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Georg Thieme Verlag KG, Rüdigerstraße 14,
70469 Stuttgart, Germany

Correspondence

Prof. Dr. Luis Apaza T.

Department of Organic Chemistry

Faculty of Sciences

University Autónoma of Madrid

Cantoblanco

Street Francisco Tomás y Valiente, 7

28049 Madrid

Spain

Tel.: +34/91/497 7622, Fax: +34/91/497 4715

lnapaza@ucm.es or luis.apaza@uam.es

Supplementary material is available under
<https://doi.org/10.1055/a-1696-6741>.

ABSTRACT

Solanum mauritianum, commonly known as “Tabaquillo”, was one of the most used plants by tribes from South America as a remedy for headaches. Based on this ethnopharmacological use, a bioguided isolation of compounds with anti-inflammatory and anti-Alzheimer's activities from *S. mauritianum* was carried out by measuring the inhibition of NF- κ B in C8D1A, Neuro-2a, and EOC 13.31 cells, and by measuring the inhibition of acetylcholinesterase and β -amyloid. This allowed the isolation and characterisation by nuclear magnetic resonance and mass spectrometry of four compounds (**1–4**). Compounds **1–4** showed NF- κ B inhibitory activity with IC₅₀ values of 9.13–9.96, 17.17–17.77, 2.41–2.79, and 1.59–1.93 μ M, respectively, while celastrol (the positive control) had an IC₅₀ value of 7.41 μ M. Likewise, compounds **1–4** showed anti-Alzheimer's activity, inhibiting the acetylcholinesterase by 40.33, 20.57, 61.26, and 83.32%, respectively, while galantamine (positive control) showed an inhibition of 90.38%. In addition, concerning the inhibition of β -amyloid aggregation, compounds **1–4** showed an inhibition of 47, 23, 65, and 93%, respectively, while curcumin (positive control) had an inhibition of 71.19%.

Introduction

Alzheimer's disease (AD) is a worldwide health problem that was noted as the sixth top cause of death in the United States in 2015 [1]. In 2015, an estimated 46.8 million people worldwide suffered from AD, and this number is expected to rise to 131.5 million in 2050 with a subsequent increase in social and financial burdens [2].

AD is a progressive and neurodegenerative disorder among the elderly, characterised by progressive loss of memory and cognition [3]. In the early stages of AD, people have trouble remembering recent events, also called short-term memory loss. In the following stages, other symptoms arise, such as problems with communication through language, disorientation, loss of motivation, neglect in self-care, sleep disorders, and behavioural issues increasing in intensity [4]. In the late stage of AD, patients may not recognise family, and gradually the brain functions are lost due to damage at the level of the central nervous system, leading to death [5].

This is caused by brain damaged neurons and neurites, and highly insoluble β -amyloid ($A\beta$) peptide deposits and intracellular neurofibrillary tangles (NFTs), providing stimuli for inflammation [6]. This inflammation in the nerve tissue is characterised by the activation of astrocytes and microglia, and by the activation of cytokines and chemokines. Microglia are the primary carriers of the inflammatory reaction, forming approximately 10 % of all brain cells. The activation of microglia is based on extracellular deposition of $A\beta$ plaques, neuronal damage induced by the toxicity of the T-protein, or after ischemic or traumatic brain injury during AD progression [7].

Moreover, the macrophage-like resident immune cells in the brain also play an inflammation role in the development of AD. Thus, the microglia are activated by oligomeric and fibrillar particles of $A\beta$ and by substances of degenerated neurons that increase their migration and phagocytosis. These main neurotoxic molecules produced by activated microglia are reactive oxygen species, glutamate, and proinflammatory cytokines (TNF- α and IL-1 β) [8].

The current diagnosis of AD is made by mental and cognitive examinations. From a histopathological point of view, this means the presence of senile $A\beta$ plaques and NFTs in brain tissue, the two main hallmarks of AD [9]. Although several compounds undergoing research appear to be protective and have therapeutic effects in the AD model, none of these drugs was able to stop or reverse the course in patients with AD [10]. Acetylcholinesterase (AChE) inhibitors are the main existing therapeutic agents for AD treatment, which temporarily decrease dementia by raising the neurotransmitter level [11]. Despite extensive studies on new drugs for AD treatment, none has been successful from this point of view, leading to the need for further research [12].

Natural compounds (natural extracts and bioactive compounds) are an emerging approach for AD therapy [13]. The first natural product studied in a clinical trial was nicotine in 1992. However, no new clinical trials were performed in the last two decades for this compound [14]. During the '90s, several other compounds were studied in clinical trials for AD therapy, such as vitamins [15]. These compounds are still being tested in human trials today. Other natural compounds have been moved to the clinical trials phase, such as curcumin (*Curcuma longa*), huperzine A (*Huperzia serrata*), and bryostatin (*Bugula neritina*), whose effects started to be evaluated in humans in 2017 [16].

In this context, *Solanum* (Solanaceae) is a genus of approximately 1230 species. Its extracts are obtained from different parts, such as leaves, stems, bark, and roots, and have been used in the ethnomedicine of different cultures [17]. Different compounds with anti-Alzheimer activity have been isolated from these species, e. g., *Solanum asperum* [18], *Solanum nigrum*, *Solanum macrocarpon* [19], and *Solanum betaceum* [20].

In this report, we analyse a different and less known species of this genus, *Solanum mauritianum* Scop., commonly known as "Tabaquillo". This species is native from north-eastern Argentina, Southern Brazil, Paraguay, and Uruguay, and the infusions from its leaves have been used in traditional medicine against fever and headaches [21, 22]. To date, only four compounds present in this species have been characterised, all of them of an alkaloid structure (solasodine, solasonine, solamargine, and caulophyllum-A) [23]. Recently, Pelo et al. [21] mentioned the presence of phenols, flavonoids, quinones, saponins, and cardiotonics through qualitative colouration reactions. Finally, with respect to the pharmacological activities of the species *S. mauritianum*, only antioxidant and antitumoral effects have been reported [24, 25].

This study reports the isolation of four compounds (**1–4**) with an inhibitory effect on NF- κ B as well as their inhibitory effect on cholinesterase and $A\beta$ aggregation.

Results and Discussion

Using hexane (HEX), dichloromethane (DCM), MeOH, and distilled water (DH₂O), four extracts of increasing polarity were obtained from dry powdered leaves of *S. mauritianum*. To evaluate their complexity and to perform an initial identification of the metabolite groups present in each of the extracts, ¹H NMR spectra of each of them was recorded (**Figs. 1S–5S**, Supporting Information). The *n*-HEX and DCM extracts showed a group of intense signals in the aliphatic zone (δ_{H} 2.5–0.5 ppm), corresponding to hydrogens located in aliphatic chains.

Moreover, the ¹H NMR spectra of *n*-HEX, DCM, and MeOH showed signals between δ_{H} 5.5–5.0 ppm, which correspond to the presence of olefinic-type protons, and around δ_{H} 4.5–3.7 ppm, corresponding to hydrogens close to heteroatoms such as ethers, amines, or alcohols. Finally, less intense signals were observed around δ_{H} 8.0–6.0 ppm, corresponding to the presence of aromatic compounds. In addition, the MeOH extract presented a group of signals at δ_{H} 1.2–0.7 ppm, which corresponds to shorter alkyl chains. Finally, the aqueous extract presented a group of signals around δ_{H} 4.5–3.5 ppm, which corresponds to glycosylated compounds.

According to the observed signals, the *n*-HEX and DCM extract contain a high concentration of fatty acids, with aromatic compounds as secondary components, while the aqueous extract contains mostly glycosides and the MeOH extract contains a variety of compounds, both free and linked to sugars.

In this report, we only include a detailed characterisation of compounds **3** and **4**, since they have not been previously reported as natural compounds, only as synthesised compounds. For compounds **1** and **2**, only a brief characterisation has been included since they have been fully described in previous works (► **Fig. 1**).

Subsequently, a comparison was made between the ^1H NMR spectra of the DCM extract and those of the resulting compounds (Fig. 6S, Supporting Information). Given the low relative mass of the compounds compared to the original extract and the complexity of the extract, it was to be expected that the signals of the compounds tended to be weaker and less defined. Signals around δ_{H} 7.2 ppm were shown in both the extract and compounds **2**, **3**, and **4**. Signals around δ_{H} 1.7–1.2 ppm in the DCM extract masked the aliphatic multiplets of compound **4**. Also, the signals of compound **1** were not easily distinguishable in the extract spectrum.

4-[(Z)-(Hydroxyimino)-methyl]-N,N-dimethylaniline (**1**) was obtained as a yellow solid; $R_f = 0.35$ (Hex/AcOEt 9:1); m.p. 140 °C; $\geq 93\%$ purity; ^1H NMR (500 MHz, CD_3OD) δ_{H} 7.96 (s, 1H/H-1'), 7.40 (dt, $J = 8.8, 1.9$ Hz, 2H/H-2), 6.70 (dt, $J = 9.0, 3.0$ Hz, 2H/H-3), 2.94 (s, 6H/ NCH_3); ^{13}C NMR (126 MHz, CD_3OD) δ_{C} 152.93/C-4, 150.98/C-1', 129.00/C-2, 121.85/C-1, 113.17/C-3, 40.45/ NCH_3 ; HR-ESI-MS $[\text{M} + \text{H}]^+ m/z = 165.1015$ and $[\text{M} + \text{Na}]^+ m/z = 187.0834$ (calculated for $\text{C}_9\text{H}_{13}\text{N}_2\text{O}$, 165.1022 and $\text{C}_9\text{H}_{12}\text{N}_2\text{NaO}$, 187.0842). The spectroscopic data obtained for compound **1** (Figs. 75–13S and Table 1S, Supporting Information) were corroborated with the available literature references [26, 27].

Phenylacetic acid (**2**) was obtained as a white solid; $R_f = 0.44$ (Hex/AcOEt 3:1); m.p. 76 °C; $\geq 98\%$ purity; ^1H NMR (300 MHz, CDCl_3) δ_{H} 11.33 (s, 1H/OH), 7.37–7.18 (m, 5H/H-2', H-3', H-4'), 3.61 (s, 2H/H-2); ^{13}C NMR (75 MHz, CDCl_3) δ_{C} 178.25/C-1, 133.37/C-1', 129.51/C-3', 128.79/C-2', 127.50/C-4', 41.21/C-2; HR-ESI-MS 136.0522 (calculated for $\text{C}_8\text{H}_8\text{O}_2$, 136.0524). The spectroscopic data obtained for compound **2** (Figs. 14S–20S and Table 2S, Supporting Information) were corroborated with the available literature references [28].

(Z)-3-[(2,5-Dimethylphenyl)-amino]-1-phenylprop-2-en-1-one (**3**) was obtained as a white solid; $R_f = 0.63$ (Hex/AcOEt, 2:1); m.p. 139 °C; $\geq 99\%$ purity (Figs. 21S–31S and Table 3S, Supporting Information). HR-ESI-MS yielded peaks for the protonated ion $[\text{M} + \text{H}]^+ m/z = 252.1373$ and the sodium adduct $[\text{M} + \text{Na}]^+ m/z = 274.1194$, accounting for a molecular formula of $\text{C}_{17}\text{H}_{17}\text{NO}$, with a degree of unsaturation of ten.

The ^1H NMR spectrum showed a total of ten signals, with a signal at δ_{H} 12.28, (1H, d, $J = 12.1$), corresponding to the NH exchangeable amine proton, two singlet signals at δ_{H} 2.41 and 2.35, each in-

tegrating for three protons, corresponding to two different methyl groups (CH_3 -2' and CH_3 -5'), and two signals at a shift of δ_{H} 7.60 (1H, dd, $J = 12.1, 7.7$) and 6.06 (1H, d, $J = 7.8$), corresponding to an olefin fragment (protons H-3 and H-2). The aromatic region showed 5 signals, 7.10 (1H, d, $J = 7.6$), 6.84 (1H, dt, $J = 7.6, 1.1$), 7.01 (1H, t, $J = 1.0$), 7.96 (2H, dt, $J = 6.2, 1.5$), and 7.55–7.39 (3H, m), that were integrated for a total of 8 protons, indicating the existence of a monosubstituted phenyl and an asymmetrically trisubstituted phenyl. Finally, the analysis of the J coupling constants on protons H-2 and H-3 led to the conclusion that the corresponding isomer of this compound is the (Z) isomer, as the 7 Hz value shown in both signals is characteristic of *cis* olefinic protons.

The ^{13}C NMR and DEPT-135 spectra showed the presence of fifteen distinct signals, corresponding to five quaternary carbon atoms, eight CH groups, and two CH_3 groups. Signals δ_{C} 127.3 and 128.3 were found in greater intensity, thus supporting the hypothesis of the existence of a monosubstituted phenyl. Likewise, the presence of a signal at δ_{C} 191.0 indicated the existence of a carbonyl group, and the signals at δ_{C} 21.2 and 17.2 confirmed the presence of two methyl groups.

The final assignment of the compound was done using the ^1H - ^1H COSY, HSQC, and HMBC spectra (► Fig. 2). The ^1H - ^1H COSY spectrum showed the presence of three independent spin systems, constituted by an olefin, a phenyl, and an aniline ring. The multiplicities of H-3', H-4', and H-6' protons, and the appearance of weak ^1H - ^1H COSY correlations between the pairs (H-2' CH_3 with H-3' and H-5' CH_3 with H-6' and H-4') allowed the placement of the methyl groups within the aniline ring. Finally, the information from the HMBC spectrum reinforced the proposed structure, showing two groups of main correlations. On the one hand, the olefin and phenyl systems showed correlations with the carbonyl group (H-2, H-3, H-1"/C-1), while the H-3 proton showed a correlation with C-1', confirming the amine bond. On the other hand, the aniline ring showed an abundance of signals that were correlated to both the atoms forming the ring and those with the methyl groups. Each of these methyl groups showed three correlations, one strong (H-2' CH_3 /C-2' and H-5' CH_3 /C-5') and two weaker (H-2' CH_3 /C-1', C-3' and H-5' CH_3 /C-4', C-6').

1-(3,4,5-Trihydroxyphenyl)-nonan-1-one (**4**) was obtained as an amber solid; $R_f = 0.44$ (Hex/AcOEt, 2:1); m.p. 156 °C; $\geq 98\%$ purity (Figs. 32S–40S and Table 4S, Supporting Information). HR-ESI-MS yielded peaks for the protonated ion $[\text{M} + \text{H}]^+ m/z = 267.1584$ and the sodium adduct $[\text{M} + \text{Na}]^+ m/z = 289.1404$, accounting for a molecular formula of $\text{C}_{15}\text{H}_{22}\text{O}_4$, with a degree of unsaturation of five.

The analysis of the ^1H NMR spectrum shows seven multiplets, with one aromatic singlet at δ_{H} 7.21, which integrates for two protons, suggesting a symmetrical tetrasubstituted phenyl ring, and two broad singlets at δ_{H} 6.14 and 5.89, suggesting the existence of two different interchangeable protons (3'-OH and 4'-OH). Likewise, a triplet type signal (2H, $J = 7.4$) was found at δ_{H} 2.88, corresponding to H-2 in position α with the carbonyl group, while the following signal, corresponding to a multiplet at δ_{H} 1.75–1.62, was correlated with H-3 in the β position with the carbonyl group. In the shift between δ_{H} 1.40–1.23, there was a multiplet signal corresponding to the rest of the CH_2 groups of the aliphatic chain. Finally, the last signal, a triplet at δ_{H} 0.88 (3H, $J = 7.0$), was assigned to a terminal methyl group.

► **Fig. 2** Structural correlation of compound 3.

► **Fig. 3** Structural correlation of compound 4.

The ^{13}C NMR and DEPT-135 spectra showed the presence of thirteen distinct signals, corresponding to four quaternary carbon atoms, a CH group, seven CH_2 groups, and a CH_3 group, signalling an aliphatic chain of eight carbon atoms. The signals at δ_{C} 108.9 and 143.7 that show a higher intensity reinforced the hypothesis of the symmetrically *tetra*-substituted phenyl. The signal at δ_{C} 201.0 pointed to the existence of a carbonyl group, and the high shifts of the quaternary aromatic carbons (C-3' and C-4') pointed to the existence of a trihydroxy derivative. The shifts of carbons (δ_{C} 29.5) and C-6 (δ_{C} 29.5) appeared very close together due to their placement in the middle of the non-functionalised aliphatic chain, which implies similar chemical environments, and thus, chemical shifts due to the absence of any significant inductive effect.

The final compound assignment was performed with the data extracted from the ^1H - ^1H COSY, HSQC, and HMBC spectra (► **Fig. 3**). The ^1H - ^1H COSY spectrum was consistent with the assignment, no further information could be extracted from it, as the CH_2 multiplet does not have the required resolution to differentiate between the individual alkyl protons. However, the HMBC spectrum showed correlations between the H-3/C-4, H-9/C-7, and H-9/C-8 pairs, which allowed their assignment. There were also signals that correlated H-2' with the rest of the aromatic carbons in addition to the carbonyl group.

Regarding the cytotoxicity of the *S. mauritanum* extracts, the results showed that the DCM (CC_{50} = 95.30–97.20 $\mu\text{g/mL}$) and aqueous (CC_{50} = 95.34–96.67 $\mu\text{g/mL}$) extracts did not show relevant cytotoxicity (p = 0.089) when compared to the actinomycin D (ACT) positive control (CC_{50} = 0.01 $\mu\text{g/mL}$) in any of the cell lines (C8D1A, Neuro-2a, and EOC 13.31) (► **Table 1**).

Concerning the anti-inflammatory capacity, the results showed that the MeOH (IC_{50} = 22.35–25.73 $\mu\text{g/mL}$) extract presented a higher inhibitory activity of the production of NF- κB than the DCM extract (IC_{50} = 26.15–27.65 $\mu\text{g/mL}$) (compared to the positive control, celastrol, IC_{50} = 3.34 $\mu\text{g/mL}$) (► **Table 2**). However, the MeOH extract did show cytotoxicity in any of the tested cell lines.

► **Table 1** CC_{50} values of the XTT (cytotoxicity) assays, calculated for the extracts from *S. mauritanum*. CC_{50} values were calculated using Prism v9.0.0 (GraphPad Software) using nonlinear regression, dose-response curves.

Extracts	Cytotoxicity (CC_{50} $\mu\text{g/mL}$) at 72 h (CI 95 %, R ²)		
	C8D1A	Neuro-2a	EOC 13.31
Untreated cells	98.23 (93.95 to 103.55, 0.9723)	98.61 (93.20 to 103.80, 0.9896)	98.92 (93.94 to 103.75, 0.9947)
DMSO	20.28 (15.02 to 25.19, 0.9682)	20.29 (15.24 to 25.25, 0.9766)	20.58 (15.45 to 25.52, 0.9684)
ACT	0.01 (–3.384 to 3.358, 0.9192)	0.01 (–3.319 to 3.332, 0.9422)	0.01 (–3.310 to 3.396, 0.9574)
EHEX	85.66 (80.55 to 90.38, 0.9382)	86.06 (81.13 to 91.23, 0.9643)	86.42 (81.38 to 91.40, 0.9425)
EDCM	95.30 (90.68 to 100.73, 0.9355)	96.52 (91.61 to 101.57, 0.9271)	97.20 (92.39 to 102.55, 0.9702)
EMeOH	75.35 (70.32 to 80.95, 0.9245)	77.54 (72.55 to 82.89, 0.9153)	77.99 (72.31 to 82.63, 0.9622)
EDH₂O	95.34 (90.14 to 100.18, 0.9441)	96.56 (91.33 to 101.99, 0.9577)	96.67 (91.37 to 101.21, 0.9915)

CI 95%: confidence interval 95%/Tukey's multiple comparisons test (***) p < 0.001). ACT = actinomycin D, EHEX = *n*-hexane extract, EDCM = dichloromethane extract, EMeOH = methanol extract, EDH₂O = aqueous extract.

Regarding the ability to inhibit AChE by *S. mauritanum* extracts, only the DCM extract inhibited AChE by 53.30 % (IC_{50} = 26.94 $\mu\text{g/mL}$) compared to galantamine (positive control), which inhibits it by 90.38 % (IC_{50} = 4.31 $\mu\text{g/mL}$) (► **Fig. 4**).

On the other hand, regarding the inhibition of A β aggregation by the extracts of *S. mauritanum*, only the DCM extract showed an inhibition of the A β aggregation by 59.02 % (IC_{50} = 26.94 $\mu\text{g/mL}$) compared to curcumin (positive control), which inhibits it by 71.19 % (IC_{50} = 3.68 $\mu\text{g/mL}$) (► **Fig. 5**).

The DCM extract was fractionated using HEX/AcOEt as the mobile phase, producing eight fractions that were subjected to cytotoxicity, anti-inflammatory, and anti-Alzheimer's assays. **Table 5S** shows the cytotoxicity results; fractions **F1–F6** showed low cytotoxicity while the last fractions (**F7** and **F8**) were highly cytotoxic. The anti-inflammatory results showed that fractions **F2** (IC_{50} = 14.99–15.94 $\mu\text{g/mL}$), **F4** (IC_{50} = 15.28–15.79 $\mu\text{g/mL}$), and **F5** (IC_{50} = 12.27–12.56 $\mu\text{g/mL}$) have the highest inhibitory activity of NF- κB production (**Table 6S**, Supporting Information). Concerning the anti-Alzheimer's activity of the fractions obtained from the DCM extract, the results showed that fractions **F2** (IC_{50} = 15.57 $\mu\text{g/mL}$), **F4** (IC_{50} = 15.51 $\mu\text{g/mL}$), and **F5** (IC_{50} = 12.37 $\mu\text{g/mL}$) inhibit AChE by 55.46, 59.70, and 56.61 %, respectively, compared to galantamine, which inhibits it by 90.38 % (IC_{50} = 4.31 $\mu\text{g/mL}$) (**Fig. 41S**, Supporting Information). Additionally, the results on the inhibition of A β aggregation confirmed that fractions **F2** (IC_{50} = 15.57 $\mu\text{g/mL}$), **F4** (IC_{50} = 15.51 $\mu\text{g/mL}$), and **F5** (IC_{50} = 12.37 $\mu\text{g/mL}$) have inhibition percentages of 60.51, 60.59, and 64.83 %, respectively, while curcumin has an inhibition rate of 71.19 % (IC_{50} = 3.68 $\mu\text{g/mL}$) (**Fig. 42S**, Supporting Information).

A total of four subfractions (**F2A–F2D**) were obtained through the chromatographic separation of fraction **F2**, which were subsequently tested through cytotoxicity, anti-inflammatory and anti-

► **Table 2** IC₅₀ values of the inhibition of NF-κB production, calculated for the extracts from *S. mauritanium*. IC₅₀ values were calculated using Prism v9.0.0 (GraphPad Software) using nonlinear regression, dose-response curves.

Extracts	Inhibition of NF-κB production (IC ₅₀ µg/mL) at 72 h (CI 95%, R2)		
	C8D1A	Neuro-2a	EOC 13.31
Untreated cells	16.76 (11.30 to 21.08, 0.9521)	18.46 (13.18 to 23.74, 0.9584)	18.73 (13.16 to 23.75, 0.9930)
Celastrol	3.34 (-2.38 to 8.06, 0.9499)	3.34 (-2.07 to 8.62, 0.9416)	3.34 (-2.65 to 8.70, 0.9442)
EHEX	36.83 (31.08 to 41.85, 0.9457)	38.12 (33.13 to 43.46, 0.9579)	39.68 (34.63 to 44.40, 0.9982)
EDCM	26.15 (21.21 to 31.21, 0.9542)	27.03 (22.83 to 32.95, 0.9637)	27.65 (22.24 to 32.27, 0.9427)
EMeOH	22.35 (17.64 to 27.15, 0.9932)	23.91 (18.28 to 28.72, 0.9687)	25.73 (20.70 to 30.30, 0.9454)
EDH ₂ O	90.53 (85.41 to 95.79, 0.9666)	90.82 (85.62 to 95.39, 0.9658)	93.34 (88.23 to 98.18, 0.9455)
CI 95 %: confidence interval 95 %/Tukey's multiple comparisons test (***)p<0.001; EHEX = <i>n</i> -hexane extract, EDCM = dichloromethane extract, EMeOH = methanol extract, EDH ₂ O = aqueous extract.			

Alzheimer's assays. **Table 7S**, Supporting Information, shows the cytotoxicity results; subfractions **F2A** and **F2B** showed low cytotoxicity when compared to the others subfractions. The anti-inflammatory results showed that subfraction **F2B** (IC₅₀ = 9.06–9.93 µg/mL) has the highest inhibitory activity of NF-κB production (**Table 8S**, Supporting Information). Concerning anti-Alzheimer's activity of the subfractions, the results showed that subfraction **F2B** (IC₅₀ = 9.47 µg/mL) inhibits AChE by 64.76% compared to galantamine, which inhibits it by 90.38% (IC₅₀ = 4.31 µg/mL) (**Fig. 43S**, Supporting Information). Additionally, the results on the inhibition of Aβ aggregation confirmed that subfraction **F2B** (IC₅₀ = 9.47 µg/mL) has an inhibition percentage of 66.51 %, while curcumin has an inhibition rate of 71.19 % (IC₅₀ = 3.68 µg/mL) (**Fig. 44S**, Supporting Information).

A total of five subfractions (**F4A–F4E**) were obtained through the chromatographic separation of fraction **F4**, which were subsequently tested through cytotoxicity, anti-inflammatory, and anti-Alzheimer's assays. **Table 9S**, Supporting Information, shows the cytotoxicity results; subfractions **F4A** and **F4B** showed low cytotoxicity when compared to the others subfractions. The anti-inflammatory results showed that subfraction **F4B** (IC₅₀ = 13.26–13.65 µg/mL) has the highest inhibitory activity of NF-κB production (**Table 10S**, Supporting Information). Concerning the anti-Alzheimer's activity of the subfractions, the results showed that subfraction **F4B** (IC₅₀ = 13.46 µg/mL) inhibits AChE by 66.87 % compared to galantamine, which has an inhibition rate of 90.38 % (IC₅₀ = 4.31 µg/mL) (**Fig. 45S**, Supporting Information). Additionally, the results on the inhibition of Aβ aggregation confirmed that subfraction **F4B** (IC₅₀ = 13.46 µg/mL) has an inhibition percentage of 69.26 %, while curcumin has an inhibition rate of 71.19 % (IC₅₀ = 3.68 µg/mL) (**Fig. 46S**, Supporting Information).

A total of four subfractions (**F5A–F5D**) were obtained through the chromatographic separation of fraction **F5**, which were subse-

► **Fig. 4** Effect of extracts from *S. mauritanium* on *in vitro* AChE inhibition. AChE inhibitory activity is expressed as % inhibition. Values are expressed as the mean ± SEM, n = 3 for each concentration (IC₅₀ obtained from the NF-κB inhibition assay).

► **Fig. 5** The Aβ aggregation inhibition activity of tested extracts from *S. mauritanium* after 72 h incubation.

quently tested through cytotoxicity, anti-inflammatory, and anti-Alzheimer's assays. **Table 11S**, Supporting Information, shows the cytotoxicity results; subfractions **F5B** and **F5C** showed low cytotoxicity when compared to the others subfractions. The anti-inflammatory results showed that subfraction **F5C** (IC₅₀ = 6.81–7.02 µg/mL) has the highest inhibitory activity of NF-κB production

► **Table 3** CC₅₀ values of the XTT (cytotoxicity) assays, calculated for the compounds from *S. mauritanum*. CC₅₀ values were calculated using Prism v9.0.0 (GraphPad Software) using nonlinear regression, dose-response curves.

Samples	Cytotoxicity (CC ₅₀ μM) at 72 h (CI 95 %, R ²)		
	C8D1A	Neuro-2a	EOC 13.31
Untreated cells	98.48 (93.93 to 103.15, 0.9424)	98.23 (93.28 to 103.35, 0.9778)	98.93 (93.94 to 103.85, 0.9728)
DMSO	10.05 (5.86 to 15.41, 0.9649)	10.07 (5.38 to 15.56, 0.9807)	10.08 (5.64 to 15.81, 0.9998)
ACT	0.008 (−4.172 to 4.120, 0.9955)	0.008 (−4.156 to 4.192, 0.9998)	0.008 (−4.132 to 4.123, 0.9454)
Compound 1	86.63 (81.45 to 91.94, 0.9605)	88.08 (83.90 to 93.74, 0.9498)	88.93 (83.64 to 93.12, 0.9928)
Compound 2	93.56 (88.56 to 98.30, 0.9652)	94.33 (89.16 to 99.43, 0.9873)	96.15 (91.13 to 101.05, 0.9895)
Compound 3	71.25 (66.16 to 76.85, 0.9913)	71.37 (66.79 to 76.52, 0.9563)	71.65 (66.70 to 76.19, 0.9313)
Compound 4	69.41 (64.01 to 74.80, 0.9718)	70.54 (65.32 to 75.73, 0.9639)	70.95 (65.17 to 75.44, 0.9492)

CI 95%: confidence interval 95%/Tukey's multiple comparisons test (***) p<0.001; ACT=actinomycin D

(Table 12S, Supporting Information). Concerning the anti-Alzheimer's activity of the subfractions, the results showed that subfraction **F5C** (IC₅₀ = 6.91 μg/mL) inhibits AChE by 62.83 % compared to galantamine, which has an inhibition rate of 90.38 % (IC₅₀ = 4.31 μg/mL) (Fig. 47S, Supporting Information). Additionally, the results on the inhibition of Aβ aggregation confirmed that subfraction **F5C** (IC₅₀ = 6.91 μg/mL) has an inhibition percentage of 65.04 % compared to curcumin, which has an inhibition percentage of 71.19 % (IC₅₀ = 3.68 μg/mL) (Fig. 48S, Supporting Information).

► **Table 3** shows the cytotoxicity of the pure compounds. Phenylacetic acid (compound 2, CC₅₀ = 93.56–96.15 μM) and 4-[(Z)-(hydroxyimino)-methyl]-N,N-dimethylaniline (compound 1, CC₅₀ = 86.63–88.93 μM) had lower cytotoxicity than the compounds (Z)-3-((2,5-dimethylphenyl)-amino)-1-phenylprop-2-en-1-one (compound 3, CC₅₀ = 71.25–71.65 μM) and 1-(3,4,5-trihydroxyphenyl)-nonan-1-one (compound 4, CC₅₀ = 69.41–70.95 μM).

Two of the four compounds showed an inhibitory capacity of NF-κB production higher than celastrol (IC₅₀ = 7.41 μM), with IC₅₀ values of 1.59–1.93 μM (compound 4) and 2.41–2.79 μM (compound 3), while the other two had a smaller inhibitory capacity than the control, with values of 9.13–9.96 μM (compound 1) and 17.17–17.77 μM (compound 2) (► **Table 4**).

Concerning anti-Alzheimer's activity of the compounds, the results showed that compound 4 (IC₅₀ = 1.74 μM) inhibited AChE by 83.32 % compared to galantamine with an inhibitory capacity of 90.38 % (IC₅₀ = 11.70 μM) (► **Fig. 6**).

► **Table 4** IC₅₀ values of the inhibition of NF-κB production, calculated for the compounds from *S. mauritanum*. IC₅₀ values were calculated using Prism v9.0.0 (GraphPad Software) using nonlinear regression, dose-response curves.

Samples	Inhibition of NF-κB production (IC ₅₀ μM) at 72 h (CI 95 %, R ²)		
	C8D1A	Neuro-2a	EOC 13.31
Untreated cells	16.24 (11.60 to 21.07, 0.9868)	18.56 (13.80 to 23.18, 0.9425)	18.86 (13.20 to 23.58, 0.9774)
Celastrol	7.41 (2.67 to 12.96, 0.9513)	7.43 (2.44 to 12.46, 0.9558)	7.48 (2.88 to 12.38, 0.9526)
Compound 1	9.13 (4.48 to 14.51, 0.9676)	9.91 (4.86 to 14.83, 0.9967)	9.96 (4.57 to 14.40, 0.9642)
Compound 2	17.17 (12.44 to 22.89, 0.9554)	17.30 (12.04 to 22.85, 0.9962)	17.77 (12.13 to 22.54, 0.9659)
Compound 3	2.41 (−3.94 to 6.41, 0.9802)	2.65 (−3.04 to 6.67, 0.9439)	2.79 (−3.51 to 6.08, 0.9967)
Compound 4	1.59 (−4.70 to 6.82, 0.9878)	1.69 (−4.45 to 6.43, 0.9518)	1.93 (−4.74 to 6.78, 0.9658)

CI 95%: confidence interval 95%/Tukey's multiple comparisons test (***) p<0.001.

► **Fig. 6** Effect of compounds from *S. mauritanum* on *in vitro* AChE inhibition. AChE inhibitory activity is expressed as % inhibition. Values are expressed as the mean ± SEM, n = 3 for each concentration (IC₅₀ obtained from the NF-κB inhibition assay).

Additionally, the results on the inhibition of Aβ aggregation confirmed that compound 4 (IC₅₀ = 1.74 μM) has an inhibition percentage of 93 % compared to curcumin, which has an inhibition percentage 71.19 % (IC₅₀ = 10 μM) (► **Fig. 7**).

Regarding the cytotoxicity of the *S. mauritanum*, an aqueous extract enriched in saponins showed cytotoxicity at a concentration of 67.02 ± 1.32 and 304.08 ± 0.47 μg/mL in the MCF-7 and HCT-116 cell lines, respectively [29]. In addition, Jayakumar and Murugan [25] indicated in their study that extracts rich in alkaloids

► **Fig. 7** The A β aggregation inhibition activity of tested compounds from *S. mauritanium* after 72 h incubation.

showed cytotoxic activity, reporting that solasodine isolated from $CHCl_3/ACOEt$ (6:4) showed cytotoxicity in MCF-7 cells, with IC_{50} values of 24.8, 47.3, and 87.4 $\mu g/mL$ at 72, 48, and 24 h respectively, whereas, caulophyllumine-A (C-A), isolated from the chloroform extract, had values of 35.6 (72 h), 54.1 (48 h), and 88.3 $\mu g/mL$ (24 h). However, our results show that the IC_{50} (cytotoxicity) values of the obtained extracts (HEX, DCM, MeOH, and DH_2O) are in the range of 85.66–96.67 $\mu g/mL$ at 72 h of treatment in the C8D1A, Neuro-2a and EOC 13.31 cell lines. Analysing the differences in the cytotoxicity values, we can conclude that the composition of the extracts influences their cytotoxic activity, with the extracts rich in alkaloids being the most cytotoxic, followed by those rich in saponins and finally those extracts rich in polyphenolic compounds, which have the lowest cytotoxicity, thus confirming the analysis of our extracts from which polyphenolic compounds were isolated while presenting low cytotoxicity (**Figs. 15–55**, Supporting Information).

On the other hand, there are no reported studies related to the anti-inflammatory activity of *S. mauritanium* extracts. However, there are reports on the anti-inflammatory *in vivo* (murine model) activity of species of the genus *Solanum*, for example, the MeOH extract of *S. nigrum* showed activity at a dose of 375 mg/kg b.w. [30], the hydroethanol extract of *Solanum lycocarpum* exhibited *in vivo* activity at the dose of 75–150 mg/kg b.w. in the later phase of inflammation [31], and the *n*-HEX and chloroform extracts of *Solanum pubescens* showed activity at a dose of 200 mg/kg b.w. [32]. These results suggest that extracts of the species *S. mauritanium* have anti-inflammatory potential.

Finally, although there are no reports on *S. mauritanium* and its effect against AD, there are reports on extracts of *Solanum gilo*, *Solanum kumba*, and *Solanum aethiopicum* that modulate the activities of enzymes in purinergic, monoaminergic, and cholinergic systems associated with AD-like symptoms, with an IC_{50} between

10–15 $\mu g/mL$ [33]. Reports on the ethanol extract from *S. betaceum* show a positive effect in the cognitive function of rats fed with doses between 100–400 mg/kg b.w., causing a decrease of levels of the *N*-methyl-D-aspartate receptor [20]. Moreover, there are reports on the MeOH extract of *Solanum virginianum* showing memory-enhancing effects on rats fed with doses between 25–100 mg/kg b.w. This effect can be partly attributed to the AChE inhibition, with an IC_{50} of 386.25 $\mu g/mL$ [34]. In this sense, we can conclude that the extracts of *S. mauritanium* have potential against AD as confirmed by previous reports on these related plants.

The four isolated compounds have been described in previous works. In relation to compound **1** (4-[(*Z*)-(hydroxyimino)-methyl]-*N,N*-dimethylaniline), it has been synthetically obtained from hydroxylamine hydrochloride and 4-(dimethylamino)-benzaldehyde [35]. Compound **2** (phenylacetic acid) is an intermediate compound of the shikimic acid pathway present in plant species [28, 36]. Regarding compound **3** ((*Z*)-3-((2,5-dimethylphenyl)-amino)-1-phenylprop-2-en-1-one), it was obtained synthetically from (*Z*)-3-(dimethylamino)-1-phenylprop-2-en-1-one and 2,5-dimethylaniline [37]. Finally, compound **4** (1-(3,4,5-trihydroxyphenyl)-nonan-1-one) is a derivative of gallic acid, previously isolated from the species *Rhodiola crenulata* [38]. However, this is the first report of the isolation of these compounds in *S. mauritanium*.

Analysing the results of the tested activities (cytotoxicity, anti-inflammatory, and anti-Alzheimer's) of the four compounds, we can observe that there is a significant difference in their pharmacological potential due to their lipophilic capacity. This is because the higher the partition coefficient ($cLog P$), the more lipophilic the compound is and, thus, it is better distributed in hydrophobic environments such as the lipid bilayers that make up cells [39]. Based on this premise, compounds **4** ($cLog P = 4.08$) and **3** ($cLog P = 3.67$) exhibit higher lipophilicity compared to compounds **1** ($cLog P = 1.91$) and **2** ($cLog P = 1.72$).

Regarding the cytotoxic effects of the isolated compounds, there are no reports of their effects on cell viability. On the other hand, regarding the anti-inflammatory activity, there are only reports on compounds **2**, **3**, and **4**. In the case of compound **2**, its anti-inflammatory effects were reported as inhibiting the induction of nitric oxide synthase, which subsequently inhibits the TNF- α and IL-1 β inflammatory mediators in astrocyte, microglial, and macrophages cell lines at an IC_{50} of 5000 μM . However, in our study, the IC_{50} value obtained for this compound was 280 times less when tested in the C8D1A, Neuro-2a, and EOC 13.31 cell lines. For compound **3**, there are reports on its anti-inflammatory effects through the inhibition of CD40-TRAF6 (a protein involved in the NF- κB pathway) in RAW 264.7 cells, with an IC_{50} of 16 μM [40]. In our study, we report that compound **3** inhibited the production of NF- κB at an IC_{50} five times less (2.41–2.79 μM) when tested in the C8D1A, Neuro-2a, and EOC 13.31 cell lines. Lastly, although compound **4** has been reported to have no substantial activity as an inhibitor of NF- κB at an IC_{50} of 1.6 μM in HEK293T (human embryonic kidney) and RAW 264.7 (mouse macrophage) cells [41], our study shows that compound **4** showed an inhibition of NF- κB production in the C8D1A, Neuro-2a and EOC 13.31 cell lines, with IC_{50} values between 1.59–1.93 μM . Therefore, if we consider that the mechanism of action of celastrol (positive control) is through the suppression of the degradation of I $\kappa B\alpha$ and inhibition of the translocation of p65

of the nucleus [42], we can conclude that all compounds act on these factors on the NF- κ B inhibition pathway.

Lastly, with regard to anti-Alzheimer's activity, there are no reports on the isolated compounds. In our case, the assay of anti-A β 42 aggregation activity was performed by the thioflavin T (ThT) method. This assay depends on the measurement of the fluorescence emitted from incubating the mixture of A β 42 with ThT at various intervals of times. Over time, the intensity of the fluorescence increases in correspondence with the degree of amyloid aggregation in the presence of ThT. The degree at which the fluorescence is quenched in the presence of an anti-Alzheimer's agent is indicative of the inhibition of the A β aggregation and, hence, the anti-Alzheimer's efficacy.

Although the percentage of AChE and A β inhibition observed for the isolated compounds is equal to or less than the positive controls (galantamine and curcumin), the concentration at which they have produced such an effect is significantly lower. To determine whether they are more or less effective than the positive controls, the assays should have been performed using the same concentrations. However, this study was not carried out to determine only anti-Alzheimer's activity, but also to determine anti-inflammatory activity. In this sense, the concentrations that were tested for anti-Alzheimer's activities were those that showed inhibition of NF- κ B.

In our study, the incubation of a mixture of 25 μ M of monomeric A β 42 and the compounds (at a concentration obtained from NF- κ B inhibition) revealed that compound **4** has a higher pharmacological potential in comparison to curcumin and the other isolated compounds, due to its binding to amyloid fibrils β 42, inhibiting their aggregation [43]. Regarding the inhibition of AChE by the isolated compounds, compound **4** showed a higher activity due to its interaction with amino acid residues defining the active site of AChE via a hydrogen bond, hydrophobic, and π - π interaction of its structure [44]. On the other hand, with respect to compound **1**, there is only one report that shows its reactivating activity of AChE (16%) at a concentration of 167 μ M [27]. However, in our case, compound **1** showed an inhibitory effect on AChE activity at a concentration 18 times less (IC_{50} = 9.5 μ M).

This work has confirmed the anti-inflammatory (NF- κ B inhibition) and anti-Alzheimer (AChE and A β inhibitions) activities of *S. mauritianum*. Moreover, this study is the first report isolating 4-[(Z)-(hydroxyimino)-methyl]-N,N-dimethylaniline (**1**), phenylacetic acid (**2**), (Z)-3-((2,5-dimethylphenyl)-amino)-1-phenylprop-2-en-1-one (**3**), and 1-(3,4,5-trihydroxyphenyl)-nonan-1-one (**4**) from *S. mauritianum*. For compounds **1** and **3**, it is the first time that they have been isolated from a natural product, given that previous authors have only obtained these compounds through chemical synthesis. The current work has shown that all four compounds can be used for low-cost formulations and efficacious herbal drugs that could be beneficial globally against Alzheimer's disease.

Material and Methods

Plant material

S. mauritianum was collected from the Cerro de Pasco community, Pasco province, Peru (10°39'53.0" S 76°15'40.5" W), in July 2019,

at an altitude of 4380 m. The botanical identification was confirmed by the International Papa Centre (No. ARV 5643).

Reagents

First grade organic solvents were used for isolating the compounds and they were purchased from Sigma-Aldrich. Column chromatography was performed with silica gel (20–45 μ m and 40–63 μ m; Merck). TLC was performed using Merck Silica gel 60-F₂₅₄ plates. Chromatograms thus obtained were visualised by UV absorbance (254 nm) and through heating a plate stained with phosphomolybdic acid (H₃PMo₁₂O₄₀) solution in EtOH.

NMR and MS analysis

NMR experiments were performed on Bruker Advance DRX 300 and 500 spectrometers operating at 300, 500 (¹H) or 76 MHz, and 126 MHz (¹³C) with tetramethylsilane (TMS) as the internal standard. Spectra were calibrated by assignment of the residual solvent peak to δ_H 7.26, δ_H 3.31, and δ_C 77.16 for CDCl₃ and δ_C 49.00 for MeOD. The complete assignment of protons and carbons was done by analysing the correlated ¹H-¹H COSY, HSQC, and HMBC spectra.

HR-ESI-MS (High-resolution electrospray ionisation mass spectrometry) analyses were performed using a mass spectrometer with a hybrid quadrupole time-of-flight analyser (model MAXIS II) from the commercial house Bruker, S.A. Samples were analysed using the electrospray ionisation technique by direct infusion at a flow of 3 μ L/min using MeOH with 0.1 % formic acid as the ionising phase. The source parameters were as follows: end plate offset: 500 V; capillary: 3500; nebuliser: 0.2 bar; dry gas: 2.0 L/min; dry temp.: 250 °C; and mass range of 50–3000 Da.

Extraction and isolation

The dry powder of the leaves of *S. mauritianum* (200 g) was extracted by repeated maceration (3 times/24 h/25 °C) with 800 mL of different solvents, increasing the polarity: HEX, DCM, MeOH, and DH₂O. Subsequently, the extracts were filtered, and the respective solvents were removed by vacuum rotary evaporation at room temperature (25 °C). As a result, four extracts of 2.8, 3, 2.5, and 13 g, respectively, were obtained.

The DCM extract (3 g) was selected as the most active one and was fractionated using a chromatographic column (12 $\times$ 60 cm) with Si-60 Silica gel (40–63 μ m; Merck) as a stationary phase and a HEX/AcOEt gradient (9:1 $\rightarrow$ 1:1 v/v) as the eluent. A total of eight fractions (**F1–F8**) were obtained, where fractions **F2** (120 mg), **F4** (213 mg), and **F5** (110 mg) showed higher biological activity.

Subsequently, based on the biological activity data, a second separation of **F2** was carried out by using a chromatographic column (2 $\times$ 50 cm) with Si-60 Silica gel (20–45 μ m; Merck) as a stationary phase and HEX/AcOEt (19:1). A total of four subfractions (**2A–2D**) were obtained, where fraction **F2B** showed higher biological activity. Finally, **F2B** was purified by a microcolumn using silica gel (20–45 μ m) as the stationary phase and HEX/AcOEt (3:1) as the mobile phase, obtaining compound **1** (6.8 mg).

Regarding **F4**, the separation was carried out using a chromatographic column (2 $\times$ 50 cm) with Si-60 Silica gel (20–45 μ m; Merck) as a stationary phase and HEX/AcOEt (3:1). A total of five subfractions (**4A–4E**) were obtained, where **F4B** showed higher biological activity. Finally, **F4B** was purified by a microcolumn using

silica gel (20–45 μm) as the stationary phase and HEX/AcOEt (3:1) as the mobile phase, obtaining compound **2** (5.3 mg).

Subsequently, the separation of **F5** was carried out by using a chromatographic column (2 $\times$ 50 cm) with Si-60 Silica gel (20–45 μm ; Merck) as a stationary phase and HEX/AcOEt (3:1). A total of four subfractions (**5A–5D**) were obtained. **F5C** (53 mg) showed higher biological activity. Finally, **F5C** was purified by a microcolumn using silica gel (20–45 μm) as the stationary phase and HEX/AcOEt (3:1) as the mobile phase, obtaining compounds **3** (6.7 mg) and **4** (4.1 mg).

A summary of the bioguided fractionation process can be observed in **Fig. 49S**, Supporting Information.

Cell culture reagents and drugs

Three *Mus musculus* cell lines were used in this study. C8D1A (mouse astrocyte, CRL-2541), Neuro-2a (mouse neuroblasts, CCL-131), and EOC 13.31 (mouse microglia, CRL-2468) cells were used as a negative control to evaluate the cytotoxicity of the samples. All cell lines were obtained from the ATCC. Cells were cultured in specific media according to ATCC recommendations. The incubation condition for all cells was in an atmosphere of 95 % air and 5 % CO_2 at 37 °C.

DMEM (Sigma-Aldrich), FBS (Summit Biotechnology), and PBS (SAFC Biosciences, Inc.) were used as culture mediums. L-glutamine was obtained from Applichem. Penicillin and streptomycin were purchased from Fisher Scientific. For cytotoxicity and activity assays, the compounds were dissolved in DMSO (Merck) at a concentration of 10 mM, while extracts and fractions were dissolved at 20 mg/mL in DMSO.

Cytotoxicity assay

Cells were seeded in 96-well plates at a density of 5×10^4 cells/well and incubated overnight at 37 °C in a humidified atmosphere of 5 % CO_2 . Stock solutions of the samples were prepared by dissolving them in DMSO at a concentration of 20 $\mu\text{g/mL}$ for the fractions and 10 μM for the compounds. Subsequently, from the stock solutions, a series of dilutions were made until a final DMSO concentration of 0.1 % was obtained in each of the wells of the plate for each of the tested concentrations [45]. The tested concentrations were 100, 50, 25, 12.50, 6.25, 3.13, 1.56, 0.78, 0.39, and 0.20 $\mu\text{g/mL}$ or μM .

The XTT viability assay, inhibition of H_2O_2 -induced cytotoxicity at various concentrations, was performed through the method of XTT formazan [46] using the abovementioned cell lines. These cells were sown in a 96-well plate and allowed to grow at 37 °C. After 72 h, the medium was removed from all wells. Fresh medium (200 μL) was added to the control wells. Cells in each test well were treated with 0.1 mM H_2O_2 (prepared in medium) along with different concentrations of the samples. ACT ($\geq 95\%$; Sigma-Aldrich, CAS Number 50–76–0) was used as a positive control at a concentration of 0.01 $\mu\text{g/mL}$ for the extract and fractions, equivalent to 0.008 μM . Cells in both control and test wells were reincubated for 72 h, maintaining the same conditions. After the treatment incubation period, the medium in each well was substituted by 200 μL of fresh medium, followed by the addition of 50 μL of XTT (0.6 mg/mL) containing 25 μM peroxymonosulfate. The plate was further incubated for 4 h in the same conditions. Absorbance was meas-

ured at 450 nm using a spectrophotometric ELISA plate reader (SpectraMax i3; Molecular Devices).

NF- κB inhibition assay

All cells were stably transfected with the KBF-Luc plasmid, which contains three copies of the NF- κB binding site (from a major histocompatibility complex promoter) fused to a minimal simian virus 40 promoter driving the luciferase gene [47]. Cells (3×10^3 for cells/well) were seeded the day before the assay on a 96-well plate. The cells were then treated with samples at the same concentrations used in the viability assays for 15 min, and then they were stimulated with 30 ng/mL TNF- α . Celastrol ($\geq 98\%$; Sigma-Aldrich, CAS Number 34157–83–0) was used as a positive control at a concentration of 3.34 $\mu\text{g/mL}$ for the extract and fractions, equivalent to 7.41 μM . After 72 h, the cells were washed twice with PBS and lysed in 50 μL lysis buffer containing 25 mM tris-phosphate (pH = 7.8), 8 mM MgCl_2 , 1 mM dithiothreitol, 1 % Triton X-100, and 7 % glycerol, during 15 min at room temperature in a horizontal shaker. Luciferase activity was measured using a GloMax 96 microplate luminometer (Promega) following the instructions of the luciferase assay kit (Promega). The RLU was calculated, and the results are expressed as percentage of inhibition of NF- κB activity induced by TNF- α (100 % activation). The experiments for each concentration of the test elements were performed in triplicate wells.

Acetylcholinesterase inhibitory activity

AChE inhibition was determined by the method described by Khan et al. [48]. Samples were solubilised in MeOH and the tested concentrations were 100, 50, 25, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4, and 0.2 $\mu\text{g/mL}$ (extracts and fractions) or μM (compounds). The reaction mixture contained 150 μL of (100 mM) sodium phosphate buffer (pH = 8.0), 10 μL of 5,5'-dithiobis-(2-nitrobenzoic acid) ($\geq 98\%$ DTNB; Sigma-Aldrich, CAS Number 69–78–3), 10 μL of test sample solution, and 20 μL of AChE solution (Sigma-Aldrich, CAS Number 9000–81–1). This mixture was homogenised and incubated for 15 min (37 °C) followed by the addition of 10 mL of acetylthiocholine iodide ($\geq 99\%$; Sigma-Aldrich, CAS Number 1866–15–5) to initiate the reaction. Galantamine hydrobromide ($\geq 94\%$; Sigma-Aldrich, CAS Number 1953–04–4) was used as a positive control at a concentration of 4.31 $\mu\text{g/mL}$ for the extract and fractions, equivalent to 11.70 μM . The assay was based on ATChI hydrolysis by AChE, obtaining 5-thio-2-nitrobenzoate anion, a mixture which turns yellow when forming complexes with DTNB. Finally, absorbance of the samples was recorded with a UV-Vis Shimadzu spectrophotometer at a wavelength of 412 nm (15 min).

Assay of β -amyloid aggregation inhibitory activity

The A β aggregation was assessed using the ThT method described by Abouelela et al. [49]. Briefly, 25 μM A β 42 (Peptide Institute, Inc.) were used; for the samples, the concentrations were the same as in the *in vitro* AChE assay, using a 50 mM sodium phosphate buffer, pH = 7.5, 100 mM NaCl, 1 % DMSO (v/v). The total fluid volume was 25 μL . Curcumin ($\geq 94\%$; Sigma-Aldrich, CAS Number 458–37–7) was used as a positive control at a concentration of 3.68 $\mu\text{g/mL}$ for the extract and fractions, equivalent to 10 μM . Reactions were incubated at 37 °C for 72 h. Aliquots were diluted fourfold into 5 μM ThT

and immediately evaluated for fluorescence (excitation = 445 nm, emission = 490 nm) to monitor the amount of A β aggregate.

Statistical analysis

Cytotoxic concentration 50 % (CC₅₀) and inhibitory concentration 50 % (IC₅₀) values were determined by nonlinear regression. All experiments were performed in triplicate. One-way ANOVA statistical analysis (Tukey's multiple comparisons test, **p<0.05; ***p<0.001) was performed to evaluate the significant differences among values. All analyses were performed using GraphPad Prism, version 9.0.0.

Supporting information

¹H NMR, ¹³C NMR, ¹H-¹H COSY, HSQC, HMBC, and MS spectra for extracts and isolated compounds are available as Supporting Information.

Acknowledgments

This work was supported by the National Herbarium of Bolivia, the Fundación de la Universidad Autónoma de Madrid (FUAM).

Conflict of Interest

The authors declare they have no conflict of interest.

References

- [1] Alzheimer's Association Alzheimer's disease facts and figures. *Alzheimer's Dement* 2015; 11: 332–384
- [2] Alzheimer's Association Alzheimer's disease facts and figures. *Alzheimer's Dement* 2020; 16: 391–460
- [3] Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. *Molecules* 2020; 25: 5789
- [4] Vaz M, Silvestre S. Alzheimer's disease: Recent treatment strategies. *Eur J Pharmacol* 2020; 887: 173554
- [5] Abeysinghe A, Deshapriya R, Udawatte C. Alzheimer's disease: a review of the pathophysiological basis and therapeutic interventions. *Life Sci* 2020; 256: 117996
- [6] Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. *Mol Neurodegener* 2020; 15: 1–37
- [7] Megur A, Baltriukienė D, Bukelskienė V, Burokas A. The Microbiota-Gut-Brain Axis and Alzheimer's Disease: Neuroinflammation Is to Blame? *Nutrients* 2020; 13: 1–24
- [8] Torres-Acosta N, O'Keefe JH, O'Keefe EL, Isaacson R, Small G. Therapeutic Potential of TNF- α Inhibition for Alzheimer's Disease Prevention. *J Alzheimer Dis* 2020; 78: 619–626
- [9] Malafaia D, Albuquerque H, Silva A. Amyloid- β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. *Eur J Med Chem* 2021; 214: 113209
- [10] Ismaili L, do Carmo Carreiras M. Multicomponent Reactions for Multitargeted Compounds for Alzheimer's Disease. *Curr Top Med Chem* 2017; 17: 3319–3327
- [11] Kokras N, Stamouli E, Sotiropoulos I, Katirtzoglou EA, Siarkos KT, Dalagiorgou G, Alexandraki KI, Coulocheri S, Piperi C, Politis AM. Acetyl Cholinesterase Inhibitors and Cell-Derived Peripheral Inflammatory Cytokines in Early Stages of Alzheimer's Disease. *J Clin Psychopharmacol* 2018; 38: 138–143
- [12] Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. *J Biomed Sci* 2020; 27: 1–13
- [13] Andrade S, Ramalho MJ, Loureiro JA, Pereira M. Natural Compounds for Alzheimer's Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. *Int J Mol Sci* 2019; 20: 2313
- [14] Hoskin JL, Al-Hasan Y, Sabbagh MN. Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update. *Nicotine Tob Res* 2019; 21: 370–376
- [15] Monacelli F, Acquarone E, Giannotti C, Borghi R, Nencioni A. Vitamin C, Aging and Alzheimer's Disease. *Nutrients* 2017; 9: 1–26
- [16] Howes MR, Fang R, Houghton PJ. Effect of Chinese Herbal Medicine on Alzheimer's Disease. *Int Rev Neurobiol* 2017; 135: 29–56
- [17] Kaunda JS, Zhang YJ. The Genus *Solanum*: An Ethnopharmacological, Phytochemical and Biological Properties Review. *Nat Prod Bioprospect* 2019; 9: 77–137
- [18] Trevisan MTS, Macedo FVV. Seleção de plantas com atividade anticolinesterase para tratamento da doença de Alzheimer. *Quim Nova* 2003; 26: 301–304
- [19] Ogunsuyi OB, Ademiluyi AO, Oboh G, Oyeleye SI, Dada AF. Green leafy vegetables from two *Solanum* spp. (*Solanum nigrum* L and *Solanum macrocarpon* L) ameliorate scopolamine-induced cognitive and neurochemical impairments in rats. *Food Sci Nutr* 2018; 6: 860–870
- [20] Safitri I, Hidayati HB, Turchan A, Suhartati, Khaerunnisa S. *Solanum betaceum* improves cognitive function by decreasing N-methyl-D-aspartate on alzheimer rats model. *Int J App Pharm* 2019; 11: 167–170
- [21] Pelo SP, Adebo OA, Green E. Chemotaxonomic profiling of fungal endophytes of *Solanum mauritianum* (alien weed) using gas chromatography high resolution time-of-flight mass spectrometry (GC-HRTOF-MS). *Metabolomics* 2021; 17: 1–13
- [22] Minghetti E, Olivera L, Montemayor SI. Ecological niche modelling of *Gargaphia decoris* (Heteroptera), a biological control agent of the invasive tree *Solanum mauritianum* (Solanales: Solanaceae). *Pest Manag Sci* 2020; 76: 1273–1281
- [23] Jayakumar K, Meenu Krishnan VG, Murugan K. Evaluation of antioxidant and antihemolytic activities of purified caulophyllumine-A from *Solanum mauritianum* Scop. *J Pharmacogn Phytochem* 2016; 5: 195–199
- [24] Jayakumar K, Murugan K. Pharmacological, Micromorphological Studies on *Solanum mauritianum* Scop. (Solanaceae): A Search. *Int J Pharm Sci Rev Res* 2015; 35: 134–139
- [25] Jayakumar K, Murugan K. Purified solasodine and caulophyllumine: a from *Solanum mauritianum* Scop. against MCF-7 breast cancer cell lines in terms of cell growth, cell cycle and apoptosis. *J Pharmacogn Phytochem* 2017; 6: 472–478
- [26] Gawinecki R, Kolehmainen E, Kauppinen R. ¹H and ¹³C NMR studies of para-substituted benzaldoximes for evaluation of the electron donor properties of substituted amino groups. *J Chem Soc Perkin Trans 2* 1998; 1: 25–30
- [27] Ribeiro TS, Prates A, Alves SR, Oliveira-Silva JJ, Riehl CAS, Figueroa-Villar JD. The effect of neutral oximes on the reactivation of human acetylcholinesterase inhibited with paraoxon. *J Braz Chem Soc* 2012; 23: 1216–1225
- [28] Liu FF, Yang XY, Hao FH, Wang YI, Tang HR. Assignments of ¹H and ¹³C NMR signals of 26 metabolites associated with the shikimate pathway. *Magn Reson Chem* 2017; 34: 311–322
- [29] Chaitanya MVNL, Dhanabal SP, Pavithra N, Rama Satyanarayana Raju K, Jubie S. Phytochemical Analysis and *In-vitro* Antioxidant and cytotoxic activity of Aerial parts of *Cestrum aurantiacum* and *Solanum mauritianum* (Solanaceae weeds of Nilgiris). *Helix* 2015; 3: 683–687
- [30] Ravi V, Saleem TSM, Patel SS, Raamamurthy J, Gauthaman K. Anti-Inflammatory effect of methanolic extract of *Solanum nigrum* Linn berries. *Int J Appl Res Nat Prod* 2009; 2: 33–36

- [31] da Costa GA, Morais MG, Saldanha AA, Assis Silva IC, Aleixo ÁA, Ferreira JM, Soares AC, Duarte-Almeida JM, Lima LA. Antioxidant, Antibacterial, Cytotoxic, and Anti-Inflammatory Potential of the Leaves of *Solanum lycocarpum* A. St. Hil. (Solanaceae). *Evid Based Complement Alternat Med* 2015; 2015: 315987
- [32] Rahman H, Rahman N, Haris M, Mahmood R. Antioxidant and anti-inflammatory potentials of *Solanum pubescens* Willd an ethnomedicinal plant of South Western Andhra Pradesh, India. *J Res Pharm* 2019; 23: 187–197
- [33] Nwanna EE, Ibukun EO, Oboh G. Eggplant (*Solanum* spp) supplemented fruits diet modulated the activities of ectonucleoside triphosphate diphosphohydrolase (ENTPase), monoamine oxidase (MAO), and cholinesterases (AChE/BChE) in the brain of diabetic Wistar male rats. *J Food Biochem* 2019; 43: e12910
- [34] Javaid U, Javaid S, Ashraf W, Rasool MF, Normal OM, Alqahtani AS, Majeed A, Shakeel W, Albekairi TH, Alqahtani F, Imran I. Chemical Profiling and Dose-Dependent Assessment of Fear Reducing and Memory-Enhancing Effects of *Solanum virginianum* in Rats. *Dose Response* 2021; 19: 1559325821998486
- [35] Seymour D, Wolfstirn KB. Substituted Styrenes. III. The Preparation of Some m- and p-Substituted α -Methylstyrenes. *J Am Chem Soc* 1948; 70: 1177–1179
- [36] Aoi Y, Tanaka K, Cook SD, Hayashi K, Kasahara H. GH3 auxin-amido synthetases alter the ratio of indole-3-acetic acid and phenylacetic acid in Arabidopsis. *Plant Cell Physiol* 2019; 61: 595–605
- [37] Tengfei Y, Wei W, Ningning C, Jinchun C. Preparation method and application of N- α unsaturated ketone compound. PA. 2020; CN112552193. https://patentscope.wipo.int/search/es/detail.jsf?docId=CN321725271&_cid=P20-KXG6XI-64400-1
- [38] Wang Y, Tao H, Huang H, Xiao Y, Wu X, Li M, Shen J, Xiao Z, Zhao Y, Du F, Ji H, Chen Y, Cho CH, Wang Y, Wang S, Wu X. The dietary supplement *Rhodiola crenulata* extract alleviates dextran sulphate sodium-induced colitis in mice through anti-inflammation, mediating gut barrier integrity and reshaping the gut microbiome. *Food Funct* 2021; 12: 3142–3158
- [39] Kapustikova I, Bak A, Gonce T, Kos J, Kozik V, Jampilek J. Investigation of Hydro-Lipophilic Properties of N-Alkoxyphenylhydroxynaphthalenecarboxamides. *Molecules* 2018; 23: 1–15
- [40] Zarzycka B, Seijkens T, Nabuurs SB, Ritschel T, Grommes J, Soehnlein O, Schrijver R, Van Tiel CM, Hackeng TM, Weber C, Giehler F, Kieser A, Lutgens E, Vriend G, Nicolaes GAF. Discovery of Small Molecule CD40-TRAF6 Inhibitors. *J Chem Inf Model* 2015; 55: 294–307
- [41] Li L, Liu Y, Chen H, Li F, Wu J, Zhang H, He J, Xing Y, Chen Y, Wang X, Tian X, Li A, Zhang Q, Huang P, Lin T, Wu Q. Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation. *Nat Chem Biol* 2015; 11: 339–346
- [42] Youn GS, Kwon DJ, Ju SM, Rhim H, Yong Soo Bae YS, Choi SY, Park J. Celastrol ameliorates HIV-1 Tat-induced inflammatory responses via NF-kappaB and AP-1 inhibition and heme oxygenase-1 induction in astrocytes. *Toxicol Appl Pharm* 2014; 280: 42–52
- [43] Sato M, Murakami K, Uno M, Nakagawa Y, Katayama S, Akagi K, Masuda Y, Takegoshi K, Irie K. Site-specific inhibitory mechanism for amyloid β 42 aggregation by catechol-type flavonoids targeting the Lys residues. *J Biol Chem* 2013; 288: 23212–23224
- [44] Katalinić M, Rusak G, Domaćinović Barović J, Sinko G, Jelić D, Antolović R, Kovarik Z. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. *Eur J Med Chem* 2010; 45: 186–192
- [45] Park CH, Martinez BC. Enhanced release of rosmarinic acid from *Coleus blumei* permeabilized by dimethyl sulfoxide (DMSO) while preserving cell viability and growth. *Biotechnol Bioeng* 1992; 40: 459–464
- [46] Tena Pérez V, Apaza Ticona L, Cabanillas HA, Maderuelo Corral S, Perles J, Rosero Valencia DF, Quintana AM, Ortega Domenech M, Rumero Sánchez Á. Antitumoral potential of carbamidocyclophanes and carbamidocylindrofridin A isolated from the cyanobacterium *Cylindrospermum stagnale* BEA 0605B. *Phytochemistry* 2020; 180: 112529
- [47] Apaza Ticona L, Rumero Sánchez Á, Sánchez Sánchez-Corral J, Iglesias Moreno P, Ortega Domenech M. Anti-inflammatory, pro-proliferative and antimicrobial potential of the compounds isolated from *Daemonorops draco* (Willd.) Blume. *J Ethnopharmacol* 2021; 268: 113668
- [48] Khan RA, Khan MR, Sahreen S. Brain antioxidant markers, cognitive performance and acetylcholinesterase activity of rats: efficiency of *Sonchus asper*. *Behav Brain Funct* 2012; 8: 1–7
- [49] Abouelela ME, Orabi M, Abdelhamid RA, Abdelkader M, Darwish F, Hotsumi M, Konno H. Anti-Alzheimer's flavanolignans from *Ceiba pentandra* aerial parts. *Fitoterapia* 2020; 143: 104541